Korrektur
Larocca A, Bonello F, Gaidano G, et al. Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood. 2021;137(22):3027-3036.
Blood · 2023
DOI: 10.1182/blood.2022018970 ↗Kurz gefasst
Korrektur in der Zeitschrift Blood, 2023. Hauptthemen laut MEDLINE: Multiple Myeloma.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Multiple MyelomaHumansAgedLenalidomideThalidomideAntineoplastic Combined Chemotherapy ProtocolsDexamethasoneTreatment Outcome
Substanzen
LenalidomideThalidomideDexamethasone
Zitieren
APA
(2023). Larocca A, Bonello F, Gaidano G, et al. Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood. 2021;137(22):3027-3036. Blood. https://doi.org/10.1182/blood.2022018970
Vancouver
Larocca A, Bonello F, Gaidano G, et al. Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood. 2021;137(22):3027-3036. Blood. 2023. doi:10.1182/blood.2022018970
BibTeX
@article{euvimed2023,
title = {Larocca A, Bonello F, Gaidano G, et al. Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood. 2021;137(22):3027-3036},
journal = {Blood},
year = {2023},
doi = {10.1182/blood.2022018970}
}
EUVIMED